Orris

19yr female high sugars AntiGAD negative cpeptide -1.9

Reading File
Checking Date & Time
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Reading File
Finding Sources
Reading File
Searching PubMed

MODY misdiagnosis type 1 diabetes young adults c-peptide

I now have sufficient information to provide a comprehensive clinical analysis. Here is the synthesis:

Clinical Analysis: 19-year-old Female, Hyperglycaemia, Anti-GAD Negative, C-peptide 1.9 nmol/L

Interpreting the Key Results

FindingSignificance
Age 19, femaleYoung-onset diabetes
Anti-GAD negativeAgainst autoimmune (Type 1) aetiology
C-peptide 1.9 nmol/LPreserved/high β-cell function — rules out absolute insulin deficiency
A C-peptide of 1.9 nmol/L is within or above the normal fasting range (~0.3–1.3 nmol/L fasting; up to ~1.7 nmol/L stimulated). This indicates robust endogenous insulin secretion is intact — the pancreatic β-cells are functioning.
Combined with a negative anti-GAD antibody, Type 1 Diabetes is essentially excluded (Type 1 = autoimmune β-cell destruction → low/absent C-peptide + positive islet autoantibodies).

Differential Diagnosis

1. MODY (Maturity-Onset Diabetes of the Young) — Top Differential

This presentation is a classic MODY "trap." Textbooks note:
"Many patients [with MODY] are misdiagnosed with type 1 diabetes and treated with insulin." — Emery's Elements of Medical Genetics and Genomics
"Phenotypically, these individuals are often not obese or insulin resistant and may initially have only modest hyperglycemia. The most common causes are mutations in HNF1A, HNF4A, or GCK." — Goodman & Gilman's Pharmacological Basis of Therapeutics
Key MODY features that fit:
  • Age <25 at diagnosis
  • Non-autoimmune (anti-GAD negative, no other islet antibodies)
  • C-peptide preserved (β-cell dysfunction, not destruction)
  • Often non-obese, no features of insulin resistance
  • Family history of diabetes across generations (autosomal dominant)
Most common MODY subtypes to consider:
TypeGeneFeaturesTreatment
MODY 3 (most common)HNF1ASensitive to sulphonylureas; progressive; renal glycosuriaSulphonylurea (very sensitive)
MODY 2GCK (Glucokinase)Mild stable fasting hyperglycaemia; rarely needs RxDiet ± no pharmacotherapy
MODY 1HNF4ASimilar to MODY 3; may respond to sulphonylureasSulphonylurea
MODY 5HNF1BRenal cysts + diabetes (RCAD syndrome)Insulin often needed

2. Type 2 Diabetes

Possible but less likely in a 19-year-old unless there is:
  • Obesity / central adiposity
  • Acanthosis nigricans
  • Metabolic syndrome features
  • Family history of T2DM
  • PCOS (common in young women → insulin resistance)
C-peptide 1.9 nmol/L would be consistent with T2DM (elevated due to insulin resistance), but anti-GAD negativity alone doesn't distinguish T2 from MODY.

3. Other Monogenic Diabetes

  • Mitochondrial diabetes (maternally inherited, may have deafness, short stature)
  • Wolfram syndrome (diabetes insipidus + DM + optic atrophy + deafness)

4. Secondary / Endocrine Causes

Less likely in a 19-year-old without obvious features, but consider if clinical signs present:
  • Cushing's syndrome (insulin resistance)
  • PCOS-related insulin resistance
  • Drug-induced (steroids, antipsychotics)

Recommended Workup

To confirm/exclude MODY:
  1. Repeat antibody panel — check anti-insulin (IAA), anti-IA2, anti-ZnT8 in addition to anti-GAD; all should be negative in MODY
  2. Family history — 3-generation pedigree; autosomal dominant pattern strongly supports MODY
  3. MODY genetic panel — NGS panel testing HNF1A, GCK, HNF4A, HNF1B, PDX1 etc.
  4. Stimulated C-peptide (post-meal or glucagon-stimulated) — if >200 pmol/L at 90 min, strongly suggests non-T1DM
  5. Urinary C-peptide:creatinine ratio (UCPCR) — >0.2 nmol/mmol suggests non-T1DM
To assess for T2DM:
  • BMI, waist circumference
  • Fasting insulin / HOMA-IR
  • Lipid profile, BP, liver USS (NAFLD)
  • PCOS assessment if clinically indicated
Other:
  • HbA1c (severity of hyperglycaemia)
  • Renal USS if HNF1B suspected (renal cysts)
  • Audiology if mitochondrial diabetes suspected

Key Clinical Pearl

In a young patient with hyperglycaemia + negative islet autoantibodies + preserved C-peptide, the most important diagnosis not to miss is MODY. Up to 80% of MODY cases are misdiagnosed as Type 1 or Type 2 DM. Correct identification matters because:
  • MODY 3 (HNF1A): responds exquisitely to low-dose sulphonylureas — can come off insulin
  • MODY 2 (GCK): may need no pharmacotherapy at all
  • Genetic diagnosis has implications for first-degree relatives
Refer to a diabetes genetics specialist or use the Exeter MODY probability calculator to estimate pre-test probability before arranging genetic testing.
Sources: Emery's Elements of Medical Genetics and Genomics; Goodman & Gilman's Pharmacological Basis of Therapeutics; Fuster & Hurst's The Heart 15th Ed; Harrison's Principles of Internal Medicine 22E; Tietz Textbook of Laboratory Medicine 7th Ed
This is a shared conversation. Sign in to Orris to start your own chat.